Blinatumomab in Children and Adolescents with Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life Multicenter Retrospective Study in Seven AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) Centers

SIMPLE SUMMARY: Blinatumomab, a bispecific T-cell engager, binding T-cell CD3 and B-cell CD19 antigens, has remarkably enlarged the treatment options for patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r BCP-ALL). The aim of our study was to retrospectively assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Beneduce, Giuliana, De Matteo, Antonia, Stellato, Pio, Testi, Anna M., Bertorello, Nicoletta, Colombini, Antonella, Putti, Maria C., Rizzari, Carmelo, Cesaro, Simone, Cellini, Monica, Barisone, Elena, Petruzziello, Fara, Menna, Giuseppe, Parasole, Rosanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773489/
https://www.ncbi.nlm.nih.gov/pubmed/35053589
http://dx.doi.org/10.3390/cancers14020426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773489/
https://www.ncbi.nlm.nih.gov/pubmed/35053589
http://dx.doi.org/10.3390/cancers14020426

Ejemplares similares